β-arrestin-dependent and -independent endosomal G protein activation by the vasopressin type 2 receptor

Reviewer #1 (Public Review):

The authors present a carefully controlled set of experiments that demonstrate an additional complexity for GPCR signalling in that endosomal signalling make be different when beta-arrestin is or isn't associated with a G protein-bound V2 vasopressin receptor. It uses state of the art biosensor-based approaches and beta-arrestin KO lines to assess this. It adds to a growing body of evidence that G proteins and beta-arresting can associate with GPCR complexes simultaneously. They also demonstrate the possibility that Gq might also be activated by the V2 receptor. My sense is one thing they may need to be considered is the possibility of such "megacomplexes" might actually involve receptor dimers or oligomers.

Reviewer #2 (Public Review):

This manuscript by Daly et al., probes the emerging paradigm of GPCR signaling from endosomes using the V2R as a model system with an emphasis on Gq/11 and β-arrestins. The study employs cellular imaging, enzyme complementation assays and energy transfer-based sensors to probe the potential formation of GPCR-G-protein-β-arrestin megaplexes. While the study is certainly very interesting, it appears to be very preliminary at many levels, and clearly requires further development in order to make robust conclusions.

1. The use of mini-G-proteins in these experiments is a major concern as these are highly engineered and may not represent the true features of G-proteins. While these have been used as a readout in other publications, their use in demonstrating megaplex formation is sub-optimal, and native, full-length G-proteins should be used.
2. The interpretation of complementation (NanoLuc) or proximity (BRET) as evidence of signaling not appropriate, especially when overexpression system and engineered constructs are being used.
3. After the original work from the same corresponding authors on megaplex formation, the major challenge in the field is to demonstrate the existence and relevance of megaplex formation at endogenous levels of components, and the current study focuses solely on showing the proximity of Gq and β-arrestins.
4. The study lacks a coherent approach, and the assays are often shifted back and forth between the two β-arrestin isoforms (1 and 2), for example, confocal vs. complementation etc.
5. In every assay, only the G-proteins and β-arrestins are monitored without a direct assessment of the presence of receptor, and absent that data, it is difficult to justify calling these entities megaplexes.

In conclusion, the authors should consider expanding on this work further to make the points more convincingly to make the work solid and impactful. The two corresponding authors are among the leaders in the field having demonstrated the existence of megaplexes, and building on the work in a systematic fashion should certainly move the paradigm forward. As the work presented in the current manuscript is already pre-printed, the authors should take this opportunity to present a completer and more comprehensive story to the field.

Reviewer #3 (Public Review):

The manuscript by Daly et al examines endosomal signaling of the vasopressin type 2 receptors using engineered mini G protein (mG proteins) and a number of novel techniques to address if sustained G protein signaling in the endosomal compartment is enhanced by β arrestin. Employing these interesting techniques they have how V2R could activates Gαs and Gα in the endosomal compartments and how this modulation could occur in arrestin dependent and independent manner. Although the phenomenon of endosomal signaling is complex to address the authors have tried their best to examine these using a number of well controlled set of experiments.